PAVmed Subsidiary Lucid Diagnostics Announces Medicare Coverage Determination for Esophageal Cancer Testing

PAVmed Inc.

MolDX Program published Future Effective Local Coverage Determination L39256 on March 30, 2023
Coverage applies to molecular testing for esophageal precancer and cancer in Medicare beneficiaries
Determination becomes effective May 14, 2023
Lucid Diagnostics is a majority-owned subsidiary of PAVmed Inc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.